SI-BONE, Inc.
NASDAQ:SIBNMedical - Devices
+$0.53 today
- Market cap
- $1.06B
- Beta
- 0.70
- P/E (TTM)
- -41.4
- EPS (TTM)
- -$0.38
Volume 1.12M
Average 0.68M
SIBN EBITDA Margin
EBITDA as a percentage of revenue.
SI-BONE, Inc.NASDAQ: SIBN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -4.0%
EBITDA Margin was -4.0% in Q1 FY2026, up 5.7 pp from a year earlier. On a trailing-twelve-month basis it was -2.9%, up 7.7 pp year over year. Over 3 fiscal years it widened by 46.2 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -2.5% for the fiscal year ending Dec 2026, up from -5.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -4.0%-8.8 pp QoQ
- Last fiscal yearDec 2025
- -5.4%+8.4 pp YoY
- LTMMar 2026
- -2.9%+7.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.7 pp | +0.9 pp | -4.8 pp |
| 1 year | +8.4 pp | +3.0 pp | -5.4 pp |
| 3 years | +46.2 pp | +7.2 pp | -39.1 pp |
| 5 years | +14.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.4%
- Year-over-year change
- +8.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.4% | +8.4pp |
| FY2024 | 2024-12-31 | -13.8% | +11.0pp |
| FY2023 | 2023-12-31 | -24.8% | +26.9pp |
| FY2022 | 2022-12-31 | -51.7% | +4.9pp |
| FY2021 | 2021-12-31 | -56.5% | — |
EBITDA Margin vs competitors
How SIBN compares with its peers on the latest reported figures
- SIBN's LTM Mar 2026 EBITDA Margin of -2.9% is the lowest of the 6 companies compared; the peer median is 21.7%.
- Its year-over-year change of +7.7 pp is the 2nd highest of 6, against a peer median of +5.9 pp.
- Over three fiscal years its change of +46.2 pp compares with a peer median of +3.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 30.1% | +6.5 pp | +0.4 pp | |
| LTM Jun 2026 | 25.9% | +5.9 pp | +3.4 pp | |
| FY2025 | 21.7% | -1.3 pp | -0.4 pp | |
| LTM Mar 2026 | 12.4% | -6.5 pp | +10.5 pp | |
| LTM Mar 2026 | -0.2% | +8.0 pp | +24.0 pp | |
| LTM Mar 2026 | -2.9% | +7.7 pp | +46.2 pp | |
| Peer median (excluding SIBN) | 21.7% | +5.9 pp | +3.4 pp | |
Competitors are the stored peer set for SIBN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 90.15M | 106.41M | 138.89M | 167.18M | 200.93M |
| Cost of Revenue | 10.43M | 15.71M | 29.47M | 35.06M | 41.05M |
| Gross Profit | 79.72M | 90.7M | 109.42M | 132.12M | 159.88M |
| Gross Margin | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% |
| Research & Development | 12.44M | 13.63M | 15.03M | 16.56M | 17.45M |
| Selling, General & Admin | 118.95M | 136.69M | 141.32M | 150.81M | 164.76M |
| Operating Expenses | 131.39M | 150.31M | 156.35M | 167.37M | 182.21M |
| Depreciation & Amortization | 2.09M | 3.45M | 5.43M | 4.38M | 2.72M |
| EBITDA | (50.97M) | (54.99M) | (34.45M) | (23.09M) | (10.91M) |
| EBITDA Margin | -56.5% | -51.7% | -24.8% | -13.8% | -5.4% |
| Operating Income | (51.67M) | (59.61M) | (46.93M) | (35.25M) | (22.33M) |
| Operating Margin | -57.3% | -56.0% | -33.8% | -21.1% | -11.1% |
| Interest Income | 186K | 1.3M | 6.92M | 7.85M | 6.07M |
| Interest Expense | 5.37M | 2.82M | 3.46M | 3.44M | 5.28M |
| Other Income / Expenses | (4.9M) | (1.65M) | 3.6M | 4.34M | 3.42M |
| Income Before Tax | (56.57M) | (61.26M) | (43.34M) | (30.91M) | (18.91M) |
| Pre-Tax Margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.57M) | (61.26M) | (43.34M) | (30.91M) | (18.91M) |
| Net Margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| EPS (Basic) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) |
| EPS (Diluted) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) |
| Weighted Avg Shares | 33.15M | 34.2M | 38.43M | 41.47M | 43.51M |
| Weighted Avg Shares (Diluted) | 33.15M | 34.2M | 38.43M | 41.47M | 43.51M |
SI-BONE, Inc.
NASDAQ:SIBN
Intrinsic Alpha fair value
Locked
Current Price
$23.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.